Investors sentiment decreased to 0 in 2019 Q2. Its down 2.00, from 2 in 2019Q1. It worsened, as 1 investors sold Allergan plc shares while 3 reduced holdings. 0 funds opened positions while 0 raised stakes. 20,340 shares or 20.57% less from 25,607 shares in 2019Q1 were reported.
American Research And Communications holds 0% or 33 shares in its portfolio. The Missouri-based Ent has invested 0% in Allergan plc (NYSE:AGN). 145 are owned by Gemmer Asset Lc. Callahan Advisors Ltd Liability has 0.38% invested in Allergan plc (NYSE:AGN) for 12,774 shares. Moreover, Staley Cap Advisers Inc has 0.02% invested in Allergan plc (NYSE:AGN). Mitchell Mcleod Pugh Williams invested in 3,982 shares. Cullinan Associate invested in 2,000 shares or 0.02% of the stock.
Allergan plc (NYSE:AGN) Ratings Coverage
Among 4 analysts covering Allergan plc Ordinary Shares (NYSE:AGN), 1 have Buy rating, 0 Sell and 3 Hold. Therefore 25% are positive. Allergan plc Ordinary Shares has $20300 highest and $13300 lowest target. $175’s average target is -6.21% below currents $186.59 stock price. Allergan plc Ordinary Shares had 15 analyst reports since June 11, 2019 according to SRatingsIntel. UBS maintained the stock with “Buy” rating in Thursday, September 12 report. The stock of Allergan plc (NYSE:AGN) earned “Buy” rating by Mizuho on Tuesday, June 25. On Tuesday, November 19 the stock rating was downgraded by UBS to “Neutral”. The firm earned “Market Perform” rating on Thursday, July 18 by Leerink Swann. The rating was initiated by Bernstein on Monday, October 14 with “Hold”. Below is a list of Allergan plc (NYSE:AGN) latest ratings and price target changes.
29/11/2019 Broker: BidaskScore Rating: Buy Downgrade
21/11/2019 Broker: BidaskScore Rating: Buy Upgrade
19/11/2019 Broker: UBS Old Rating: Buy New Rating: Neutral Old Target: $189.0000 New Target: $203.0000 Downgrade
04/11/2019 Broker: BidaskScore Rating: Buy Upgrade
26/10/2019 Broker: BidaskScore Rating: Hold Downgrade
14/10/2019 Broker: Bernstein Rating: Hold New Target: $180 Initiate
01/10/2019 Broker: BidaskScore Rating: Buy Upgrade
12/09/2019 Broker: UBS Rating: Buy Old Target: $172.0000 New Target: $189.0000 Maintain
07/08/2019 Broker: Guggenheim Old Rating: Buy New Rating: Neutral Downgrade
18/07/2019 Broker: Leerink Swann Old Rating: Outperform New Rating: Market Perform Old Target: $217.0000 New Target: $188.0000 Downgrade
The stock increased 0.81% or $1.5 during the last trading session, reaching $186.59. About 976,530 shares traded. Allergan plc (NYSE:AGN) has declined 12.77% since December 4, 2018 and is downtrending. It has underperformed by 12.77% the S&P500.
Allergan plc, a specialty pharmaceutical company, develops, makes, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. The company has market cap of $61.25 billion. It operates through US Specialized Therapeutics, US General Medicine, and International divisions. It currently has negative earnings. The firm offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, womenÂ’s health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as AlzheimerÂ’s disease.
More notable recent Allergan plc (NYSE:AGN) news were published by: Seekingalpha.com which released: “Stocks To Watch: ViacomCBS, Amazon’s AWS Event And Conference Blitz – Seeking Alpha” on November 30, 2019, also Prnewswire.com with their article: “Allergan Announces Positive Phase 3 ACHIEVE II Trial Results for Ubrogepant Published in The Journal of the American Medical Association – PRNewswire” published on November 19, 2019, Fool.com published: “Better Buy: AbbVie vs. GlaxoSmithKline – The Motley Fool” on November 24, 2019. More interesting news about Allergan plc (NYSE:AGN) were released by: Fool.com and their article: “Why Editas Medicine Shares Jumped Today – Motley Fool” published on November 25, 2019 as well as Fool.com‘s news article titled: “Better Buy: Eli Lilly vs. AbbVie – Motley Fool” with publication date: November 17, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.